Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

More than Half of All Opioid Prescriptions Go to People with Mental Illness

By University of Michigan | July 3, 2017

Fifty-one percent of all opioid medications distributed in the U.S. each year are prescribed to adults with mood disorders such as depression and anxiety, according to new research from the University of Michigan and the Geisel School of Medicine at Dartmouth. 

“Despite representing only 16 percent of the adult population, adults with mental health disorders receive more than half of all opioid prescriptions distributed each year in the United States,” said Matthew Davis, lead author of the study and assistant professor at the U-M School of Nursing. 

Overall, of the 115 million prescriptions written for opiates each year, 60 million are written for adults with mental illness. 

The study, “Prescription opioid use among adults with mental health disorders in the United States,” is among the first to show the extent to which the population of Americans with mental illness use opioids. It is scheduled to be published online July 6 in the Journal of the American Board of Family Medicine.

Researchers found that among the 38.6 million Americans diagnosed with mental health disorders, more than 7 million, or 18 percent, are prescribed opioids each year. By comparison, only 5 percent of adults without mental disorders are likely to use prescription opioids. 

“Because of the vulnerable nature of patients with mental illness, such as their susceptibility for opioid dependency and abuse, this finding warrants urgent attention to determine if the risks associated with such prescribing are balanced with therapeutic benefits,” said study co-author Brian Sites, an anesthesiologist at Dartmouth-Hitchcock Medical Center.

The connection between mental illness and opioid prescribing is particularly concerning because mental illness is also a prominent risk factor for overdose and other adverse opioid-related outcomes, Sites and Davis say.

(Source: EurekAlert!)

Related Articles Read More >

These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
Thermo Fisher Scientific
Thermo Fisher to invest $2B on U.S. manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE